Optimizing Outcomes in Myeloma

Amy Pierre, MSN, ANP-BC, Flatiron Health and Memorial Sloan Kettering, New York, NY and Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC Recorded on March 10, 2026 Amy Pierre, MSN, ANP-BC Senior Clinical Director, Research Oncology, Flatiron Health Nurse Practitioner, Memorial Sloan Kettering Cancer Center New York, NY Peter Voorhees, MD Director, Outreach for Hematologic Malignancies, Plasma Cells Disorder Program, Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute Charlotte, NC Professor, Cancer Medicine Wake Forest University School of Medicine Winston-Salem, NC In this episode, Dr. Peter Voorhees from the Levine Cancer Institute and Amy Pierre, MSN, RN, ANP BC from Flatiron Health and Memorial Sloan Kettering, break down the evolving landscape of myeloma, from early signs and diagnostic criteria to frontline therapy, transplant decisions, and T- cell redirecting therapies. They explore real world challenges in survivorship, treatment toxicity, and disparities in access to advanced therapies, offering practical insights to help care teams support patients more effectively. Tune in for an informative and forward looking discussion shaping the future of myeloma management. Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients